Back to Search Start Over

Yuanhuatine from Daphne genkwa selectively induces mitochondrial apoptosis in estrogen receptor α-positive breast cancer cells in vitro.

Authors :
Zhang YY
Shang XY
Hou XW
Li LZ
Wang W
Hayashi T
Zhang Y
Yao GD
Song SJ
Source :
Planta medica [Planta Med] 2019 Nov; Vol. 85 (16), pp. 1275-1286. Date of Electronic Publication: 2019 Oct 18.
Publication Year :
2019

Abstract

Breast cancer is one of the most common cancers diagnosed among women worldwide. Estrogen receptor alpha (ER α ) is a transcriptional factor that plays an important role in the development and progression of breast cancer. Yuanhuatine, a natural daphnane-type diterpenoid extracted from Daphne genkwa , was reported to exhibit significant cytotoxicity against breast cancer cells. However, the underlying mechanism is still unclear. In this study, we evaluated the cytotoxicity of yuanhuatine on two breast cancer cell lines that are ER α -positive and -negative. The results show that yuanhuatine inhibits the growth of ER α -positive cells (MCF-7) with much stronger inhibitory activity (IC <subscript>50</subscript>  = 0.62 µM) compared with positive control tamoxifen (IC <subscript>50</subscript>  = 14.43 µM). However, no obvious cytotoxicity was observed in ER α -negative cells (MDA-MB-231). Subsequent experiment also indicated that yuanhuatine markedly induced mitochondrial dysfunction, leading to apoptosis in MCF-7 cells. Molecular docking studies suggest the potential interactions between yuanhuatine and ER α . Immunofluorescence staining and Western blot analysis indicated that yuanhuatine down-regulated the expression of ER α in MCF-7 cells. MPP, a specific ER α inhibitor, significantly enhanced yuanhuatine-induced mitochondrial dysfunction and apoptosis in MCF-7 cells. On the contrary, the treatment with yuanhuatine causes no apoptosis in MM231 cells. Altogether, in vitro and in silico results suggested that ER α down-regulation was involved in yuanhuatine-induced mitochondrial dysfunction and apoptosis in ER α -positive breast cancer cells. Thus, yuanhuatine could be a potential candidate for treating ER α -positive breast cancer.<br />Competing Interests: The authors declare that they have no conflict of interest.<br /> (Georg Thieme Verlag KG Stuttgart · New York.)

Details

Language :
English
ISSN :
1439-0221
Volume :
85
Issue :
16
Database :
MEDLINE
Journal :
Planta medica
Publication Type :
Academic Journal
Accession number :
31627219
Full Text :
https://doi.org/10.1055/a-1013-1439